Back20/20 Biolabs Common Stock Overview

20/20 Biolabs Common Stock Profit Margin

Valuation check: AIDX's profit margin is -340.92%, below the sector sector average of 22.52%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-376.78%

As of Jun 2026

Annual Profit Margin (TTM)

-340.92%

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading
Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

20/20 Biolabs Common Stock (AIDX) FAQ

The latest profit margin for AIDX is -340.92% as of June 2026. That is below the sector sector average of 22.52%. Investors often review this figure alongside 20/20 Biolabs Common Stock's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, AIDX currently prints -340.92% for profit margin, while the sector average sits near 22.52%. That is roughly 1613.8% below the sector mean. Large gaps often invite a closer look at 20/20 Biolabs Common Stock's growth, margins, and balance sheet.

Profit Margin shows how effectively 20/20 Biolabs Common Stock converts resources into returns. At -340.92%, AIDX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AIDX's profit margin (-340.92%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.